These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29309700)

  • 1. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site.
    Messenger KM; Davis JL; LaFevers DH; Barlow BM; Posner LP
    Vet Anaesth Analg; 2011 Jul; 38(4):374-84. PubMed ID: 21501371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers.
    Wang J; Chen X; Yuan B; Wang W; Xu C; Zhao W; Zhao P; Wang Y; Zhao X; Wang Y
    Clin Ther; 2018 Oct; 40(10):1683-1691. PubMed ID: 30241688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of sublingual buprenorphine.
    Mendelson J; Upton RA; Everhart ET; Jacob P; Jones RT
    J Clin Pharmacol; 1997 Jan; 37(1):31-7. PubMed ID: 9048270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.
    Willsie SK; Evashenk MA; Hamel LG; Hwang SS; Chiang YK; Palmer PP
    Clin Ther; 2015 Jan; 37(1):145-55. PubMed ID: 25544247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absolute bioavailability of racemic ketamine from a novel sublingual formulation.
    Rolan P; Lim S; Sunderland V; Liu Y; Molnar V
    Br J Clin Pharmacol; 2014 Jun; 77(6):1011-6. PubMed ID: 24977293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
    Bai SA; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers.
    Lim CB; Schug SA; Sunderland VB; Paech MJ; Liu Y
    Anesth Analg; 2012 Sep; 115(3):554-9. PubMed ID: 22584544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
    Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
    Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
    Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
    Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
    Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
    J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.